Aclaris Therapeutics (NASDAQ:ACRS – Get Rating) and NeuroSense Therapeutics (NASDAQ:NRSN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Analyst Recommendations This is a summary of recent ratings […]
NeuroSense Therapeutics Granted Patent in Canada for its ALS Drug PrimeC - read this article along with other careers information, tips and advice on BioSpace
NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises - Warrants exercised at $6 per share - Extends cash runway through Q3 2023 . | March 25, 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS - PrimeC, a novel combination therapy, demonstrated efficacy and safety in Phase IIa. | March 21, 2022